NASDAQ:CBIO

Catalyst Biosciences (CBIO) Stock Forecast, Price & News

$0.48

-0.01 (-2.03%)

(As of 09/29/2023 ET)

Compare

Today's Range: $0.47
▼
$0.50
50-Day Range: $0.33
▼
$0.65
52-Week Range: $0.19
▼
$0.74

Volume: 119,508 shs
Average Volume: 245,753 shs
Market Capitalization: $18.31 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Catalyst Biosciences MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.27% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.62
Upright™ Environmental Score
News Sentiment: 0.84
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.16) to ($0.03) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

685th out of 970 stocks

Pharmaceutical Preparations Industry

325th out of 450 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Catalyst Biosciences.

5.0

Short Interest

Percentage of Shares Shorted
0.27% of the outstanding shares of Catalyst Biosciences have been sold short.
Short Interest Ratio / Days to Cover
Catalyst Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Catalyst Biosciences has recently decreased by 37.73%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Catalyst Biosciences does not currently pay a dividend.
Dividend Growth
Catalyst Biosciences does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Catalyst Biosciences has received a 57.94% net impact score from Upright. Catalyst Biosciences seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is driven by its "Preclinical research services for physical health" and "Basic medical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Catalyst Biosciences is -0.62.

3.2

News and Social Media Coverage

News Sentiment
Catalyst Biosciences has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Catalyst Biosciences this week, compared to 0 articles on an average week.
MarketBeat Follows
1 people have added Catalyst Biosciences to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Catalyst Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.00% of the stock of Catalyst Biosciences is held by insiders.
Percentage Held by Institutions
Only 5.98% of the stock of Catalyst Biosciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Catalyst Biosciences are expected to grow in the coming year, from ($0.16) to ($0.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Catalyst Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Catalyst Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Catalyst Biosciences (NASDAQ:CBIO) Stock

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

CBIO Price History

30 days | 90 days | 365 days | Advanced Chart

CBIO Stock News Headlines

September 29, 2023 | americanbankingnews.com

Catalyst Biosciences, Inc. (NASDAQ:CBIO) Sees Significant Decrease in Short Interest

September 26, 2023 | americanbankingnews.com

Catalyst Biosciences (NASDAQ:CBIO) Stock Crosses Above 200 Day Moving Average of $0.32

September 30, 2023 | The Oxford Club (Ad)

Better Than Oil Stocks?

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

August 23, 2023 | finance.yahoo.com

Is Catalyst Biosciences (CBIO) Significantly Overvalued?

August 22, 2023 | investing.com

Catalyst Biosciences (CBIO) Earnings Dates & Reports

June 9, 2023 | finance.yahoo.com

CBIO - Catalyst Biosciences, Inc.

April 28, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHBI, CBIO, TA, ASRT

April 3, 2023 | finance.yahoo.com

Catalyst Biosciences, Inc. (NASDAQ:CBIO) insiders placed bullish bets worth US$941k in the last 12 months

September 30, 2023 | The Oxford Club (Ad)

Better Than Oil Stocks?

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

March 31, 2023 | insidermonkey.com

5 Cheap Healthcare Stocks to Buy in 2023

March 31, 2023 | markets.businessinsider.com

Raymond James Sticks to Its Hold Rating for Catalyst Biosciences (CBIO)

March 29, 2023 | finance.yahoo.com

12 Cheap Healthcare Stocks to Buy in 2023

March 9, 2023 | prnewswire.com

CATALYST BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Catalyst Biosciences, Inc. - CBIO

February 28, 2023 | msn.com

Catalyst Biosciences Shares Are Rallying: What's Driving The Action?

February 28, 2023 | finance.yahoo.com

Catalyst Biosciences Provides Corporate Update

February 27, 2023 | finance.yahoo.com

GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology

February 5, 2023 | morningstar.com

Catalyst/Millburn Hedge Strategy I

January 19, 2023 | insidermonkey.com

5 Stocks with the Lowest PE Ratio

January 4, 2023 | prnewswire.com

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Catalyst Biosciences, Inc. - CBIO

December 29, 2022 | wsj.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Catalyst Biosciences, Inc. Merger

December 29, 2022 | benzinga.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MPB, BLI, ISO, CBIO

December 28, 2022 | benzinga.com

CBIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Catalyst Biosciences, Inc. Is Fair to Shareholders

November 16, 2022 | finance.yahoo.com

Catalyst Biosciences Third Quarter 2022 Earnings: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)

October 7, 2022 | fool.com

How Much Could This Catalyst Boost Shiba Inu in October?

September 24, 2022 | seekingalpha.com

CBIO Catalyst Biosciences, Inc.

September 1, 2022 | finance.yahoo.com

Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share

August 25, 2022 | finance.yahoo.com

Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share

See More Headlines

Receive CBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CBIO Company Calendar

Last Earnings: 8/17/2023
Today: 9/30/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:CBIO
CUSIP: 87611R30
CIK: 1124105
Web: www.catalystbiosciences.com
Phone: (650) 871-0761
Fax: 336-480-2107
Employees: 7
Year Founded: 2003

Profitability

EPS (Most Recent Fiscal Year): ($1.50)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,240,000.00
Net Margins: N/A
Pretax Margin: -994.21%
Return on Equity: -364.68%
Return on Assets: -230.82%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.73
Quick Ratio: 2.73

Sales & Book Value

Annual Sales: $790,000.00
Price / Sales: 23.18
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.69) per share
Price / Book: -0.70

Miscellaneous

Outstanding Shares: 37,970,000
Free Float: 36,456,000
Market Cap: $18.31 million
Optionable: Optionable
Beta: 1.02

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Nassim Usman Ph.D. (Age 63)
Pres, CEO & Director
Comp: $1.75M

Ms. Seline E. Miller CPA (Age 54)
Sr. VP of Fin., Interim Chief Financial & Principal Accounting Officer
Comp: $707.55k

Ms. Ana Kapor
Sr. Director of Investor Relations & Corp. Communications

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CBIO Stock - Frequently Asked Questions

How have CBIO shares performed in 2023?: Catalyst Biosciences' stock was trading at $0.5275 at the beginning of the year. Since then, CBIO shares have decreased by 8.6% and is now trading at $0.4823.
View the best growth stocks for 2023 here.
Are investors shorting Catalyst Biosciences?: Catalyst Biosciences saw a decline in short interest in September. As of September 15th, there was short interest totaling 103,000 shares, a decline of 37.7% from the August 31st total of 165,400 shares. Based on an average daily volume of 411,500 shares, the days-to-cover ratio is presently 0.3 days.
View Catalyst Biosciences' Short Interest.
When is Catalyst Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our CBIO earnings forecast.
How were Catalyst Biosciences' earnings last quarter?: Catalyst Biosciences, Inc. (NASDAQ:CBIO) posted its quarterly earnings results on Thursday, August, 17th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.07).
How often does Catalyst Biosciences pay dividends? What is the dividend yield for Catalyst Biosciences?: Catalyst Biosciences declared a dividend on Wednesday, January 4th. Investors of record on Monday, January 16th will be paid a dividend of $0.24 per share on Thursday, January 12th. This represents a yield of 285.47%. The ex-dividend date of this dividend is Friday, January 13th.
Read our dividend analysis for CBIO.
When did Catalyst Biosciences' stock split?: Catalyst Biosciences's stock reverse split on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Catalyst Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Imunon (CLSN).
What is Catalyst Biosciences' stock symbol?: Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."
How do I buy shares of Catalyst Biosciences?: Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Catalyst Biosciences' stock price today?: One share of CBIO stock can currently be purchased for approximately $0.48.
How much money does Catalyst Biosciences make?: Catalyst Biosciences (NASDAQ:CBIO) has a market capitalization of $18.31 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-8,240,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.
How can I contact Catalyst Biosciences?: Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.catalystbiosciences.com. The biopharmaceutical company can be reached via phone at (650) 871-0761, via email at investors@catbio.com, or via fax at 336-480-2107.

This page (NASDAQ:CBIO) was last updated on 9/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial